Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

2(40.0%)

Phase 4

1(20.0%)

Phase 3

1(20.0%)

Phase 2

1(20.0%)

5Total

N/A(2)

Phase 4(1)

Phase 3(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT02936219Active Not Recruiting

The PREWEAN Study. Weaning of Preterm Infants During the First Year of Life.

Role: collaborator

NCT04351724Phase 2Unknown

Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)

Role: collaborator

NCT02974777Phase 4Withdrawn

The IDEAL-PCI Extended Registry

Role: lead

NCT01515345Phase 3Completed

Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry

Role: lead

NCT02581852Not ApplicableCompleted

Workability in Patients With Seropositive Rheumatoid Arthritis

Role: lead

NCT01775111Not ApplicableUnknown

Influence of Strength Training and Protein Supplementation on Fitness of Institutionalized Elderly

Role: collaborator

All 6 trials loaded